论文部分内容阅读
Obesity and type 2 Diabetes Mellitus (T2DM) are increasing worldwide, especially in developing countries.While T2DM is considered a coronary risk equivalent, apart from metformin all other glycaemia-focused interventions have failed in substantially reducing macrovascular complications.